In the Phase III Lp(a)HORIZON trial of 8,323 patients with elevated lipoprotein(a) and established cardiovascular disease, pelacarsen lowered Lp(a) but did not significantly reduce cardiovascular death, heart attack, stroke, or urgent revascularization compared with placebo on top of guideline-directed therapy. The result separates a validated genetic risk marker from demonstrated clinical benefit when that marker is pharmacologically lowered. Full data, including potential subgroup effects among those with the highest Lp(a), are pending presentation at a medical congress.
Key Points
- Pelacarsen lowered Lp(a) but missed primary cardiovascular outcome endpoint
- Trial enrolled 8,323 high-Lp(a) patients on optimized standard therapy
- Roughly one in five people carry inherited elevated Lp(a)
Longevity Analysis
Lp(a) remains a genuine inherited risk marker, measurable once in a lifetime and largely unmoved by diet or training — but moving the number is not yet proven to move the event rate. That distinction matters for anyone building a cardiovascular strategy around biomarkers: a measurable signal identifies who carries risk without automatically identifying which intervention resolves it, and arterial risk is driven by cholesterol deposition, clotting tendency, and vessel wall inflammation acting together rather than by a single particle in isolation. Until outcome data support pharmacologic Lp(a) lowering, the durable levers remain blood pressure control, apoB and LDL management, metabolic health, and the daily practices that protect vascular function over decades.
Original published by Longevity.Technology, by Kyle Umipig.